CCL2 is induced by chemotherapy and protects prostate cancer cells from docetaxel-induced cytotoxicity.

Publication Type:

Journal Article

Source:

The Prostate, Volume 70, Issue 4, p.433-42 (2010)

Keywords:

2010, Antineoplastic Agents, APOPTOSIS, Cell Line, Tumor, Cell Survival, Center-Authored Paper, Chemokine CCL2, Clinical Research Division, Drug Resistance, Neoplasm, Drug Therapy, Combination, gene expression, Gene Expression Profiling, Gene Silencing, Genomics Core Facility, Human Biology Division, Humans, Male, MITOXANTRONE, Prostatic Neoplasms, Recombinant Proteins, RNA, Messenger, RNA, Small Interfering, Shared Resources, Taxoids, Up-Regulation

Abstract:

Metastatic prostate cancer is either inherently resistant to chemotherapy or rapidly acquires this phenotype after chemotherapy exposure. In this study, we identified a docetaxel-induced resistance mechanism centered on CCL2.